Alejandro Dorenbaum
Chief Tech/Sci/R&D Officer bij RENEO PHARMACEUTICALS, INC.
Vermogen: 49 800 $ op 31-03-2024
Profiel
Alejandro Dorenbaum is currently a Clinical Professor-Pediatrics at Stanford University School of Medicine and the Chief Medical Officer at Reneo Pharmaceuticals, Inc. He previously worked as the Director-Clinical Development at Chiron Corp., Medical Director at Genentech, Inc., Senior Director-Clinical Affairs at BioMarin Pharmaceutical, Inc., Chief Medical Officer at Lumena Pharmaceuticals, Inc., Assistant Clinical Professor-Pediatrics at The University of California, San Francisco, and Chief Medical Officer at Allakos, Inc. Dr. Dorenbaum holds a doctorate degree from Universidad Nacional Autónoma de México.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 09-12-2022 | 30 000 ( 0.09% ) | 49 800 $ | 31-03-2024 |
Actieve functies van Alejandro Dorenbaum
| Bedrijven | Functie | Begin |
|---|---|---|
| RENEO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-01-2018 |
| Stanford University School of Medicine | Corporate Officer/Principal | - |
Eerdere bekende functies van Alejandro Dorenbaum
| Bedrijven | Functie | Einde |
|---|---|---|
| ALLAKOS INC. | Chief Tech/Sci/R&D Officer | 01-06-2017 |
Lumena Pharmaceuticals, Inc.
 Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 30-06-2014 |
| BIOMARIN PHARMACEUTICAL INC. | Chief Tech/Sci/R&D Officer | 01-01-2009 |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Corporate Officer/Principal | 01-01-2003 |
| The University of California, San Francisco | Corporate Officer/Principal | 01-01-2000 |
Opleiding van Alejandro Dorenbaum
| Universidad Nacional Autónoma de México | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| ALLAKOS INC. | Health Technology |
| RENEO PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Lumena Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Health Technology |
